Arzika AM, Abdou A, Maliki R, Beido N, Kadri B, Harouna AN, Galo AN, Alio MK, Lebas E, Oldenburg CE et al..  2024.  Prolonged mass azithromycin distributions and macrolide resistance determinants among preschool children in Niger: A sub-study of a cluster-randomized trial (MORDOR).. PLoS Med. 21(5):e1004386.

Doan T, Worden L, Hinterwirth A, Arzika AM, Maliki R, Abdou A, Zhong L, Chen C, Cook C, Lebas E et al..  2020.  Macrolide and Nonmacrolide Resistance with Mass Azithromycin Distribution.. N Engl J Med. 383(20):1941-1950.

Hinterwirth A, Sie A, Coulibaly B, Ouermi L, Dah C, Tapsoba C, Zhong L, Chen C, Lietman TM, Keenan JD et al..  2020.  Rapid Reduction of  Species in the Gut Microbiome of Preschool Children after Oral Azithromycin: A Randomized Controlled Trial.. Am J Trop Med Hyg. 103(3):1266-1269.

Sie A, Ouattara M, Bountogo M, Bagagnan C, Coulibaly B, Boudo V, Lebas E, Brogdon JM, Lin Y, Bärnighausen T et al..  2019.  A double-masked placebo-controlled trial of azithromycin to prevent child mortality in Burkina Faso, West Africa: Community Health with Azithromycin Trial (CHAT) study protocol.. Trials. 20(1):675.

Keenan JD, Arzika AM, Maliki R, Boubacar N, Adamou SElh, Ali MMoussa, Cook C, Lebas E, Lin Y, Ray KJ et al..  2019.  Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in Africa.. N Engl J Med. 380(23):2207-2214.

Lietman TM, Doan T, Keenan JD.  2019.  Macrolide Resistance and Longer-Term Assessment of Azithromycin in MORDOR I. Reply.. N Engl J Med. 381(22):2184-2185.